Sanofi unit takes CSL to court over haemophilia therapy

Biotech company Bioverativ has accused CSL Behring of infringing three patents covering its haemophilia B treatment Alprolix (coagulation factor IX (Recombinant), Fc fusion protein).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

French healthcare company makes $1.2bn AI drug discovery deal

18 August 2022 Partnership with San Francisco-based software biotech initially focuses on compounds for five targets | Company uses machine learning to enable structure-based drug design.

Americas

Sanofi to buy Bioverativ for $11.6bn

23 January 2018 Paris-based Sanofi has revealed plans to acquire Bioverativ, a US-based biotech company focused on haemophilia treatments.

Americas

USITC begins probe into CSL Behring

10 August 2017 The US International Trade Commission has instituted a probe into CSL Behring, a biopharmaceutical company.

More on this story

Americas

French healthcare company makes $1.2bn AI drug discovery deal

18 August 2022 Partnership with San Francisco-based software biotech initially focuses on compounds for five targets | Company uses machine learning to enable structure-based drug design.

Americas

Sanofi to buy Bioverativ for $11.6bn

23 January 2018 Paris-based Sanofi has revealed plans to acquire Bioverativ, a US-based biotech company focused on haemophilia treatments.

Americas

USITC begins probe into CSL Behring

10 August 2017 The US International Trade Commission has instituted a probe into CSL Behring, a biopharmaceutical company.

More on this story

Americas

French healthcare company makes $1.2bn AI drug discovery deal

18 August 2022 Partnership with San Francisco-based software biotech initially focuses on compounds for five targets | Company uses machine learning to enable structure-based drug design.

Americas

Sanofi to buy Bioverativ for $11.6bn

23 January 2018 Paris-based Sanofi has revealed plans to acquire Bioverativ, a US-based biotech company focused on haemophilia treatments.

Americas

USITC begins probe into CSL Behring

10 August 2017 The US International Trade Commission has instituted a probe into CSL Behring, a biopharmaceutical company.